Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 322

1.

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJGM, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Silvestri NJ, Conwit R, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group.

Lancet Neurol. 2019 Mar;18(3):259-268. doi: 10.1016/S1474-4422(18)30392-2. Epub 2019 Jan 25.

2.

Randomized Trial of Thymectomy in Myasthenia Gravis.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BR, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Garcia Ramos GS, Verschuuren JJ, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Conwit R, Odenkirchen J, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group.

N Engl J Med. 2016 Aug 11;375(6):511-22. doi: 10.1056/NEJMoa1602489. Erratum in: N Engl J Med. 2017 May 25;376(21):2097. [Dosage error in article text].

3.

Prospective study into the incidence of Lambert Eaton myasthenic syndrome in small cell lung cancer.

Payne M, Bradbury P, Lang B, Vincent A, Han C, Newsom-Davis J, Talbot D.

J Thorac Oncol. 2010 Jan;5(1):34-8. doi: 10.1097/JTO.0b013e3181c3f4f1.

4.

Voluntary partial retraction of: Recessive inheritance and variable penetrance of slow-channel congenital myasthenic syndromes.

Croxen R, Hatton C, Shelley C, Brydson M, Chauplannaz G, Oosterhuis H, Vincent A, Newsom-Davis J, Colquhoun D, Beeson D.

Neurology. 2009 Jan 20;72(3):294. doi: 10.1212/01.wnl.0000344248.36823.b5. No abstract available.

PMID:
19153382
5.

The myasthenia gravis thymus: a rare source of human autoantibody-secreting plasma cells for testing potential therapeutics.

Hill ME, Shiono H, Newsom-Davis J, Willcox N.

J Neuroimmunol. 2008 Sep 15;201-202:50-6. doi: 10.1016/j.jneuroim.2008.06.027. Epub 2008 Aug 22.

PMID:
18722675
6.

The MGTX experience: challenges in planning and executing an international, multicenter clinical trial.

Aban IB, Wolfe GI, Cutter GR, Kaminski HJ, Jaretzki A 3rd, Minisman G, Conwit R, Newsom-Davis J; Mgtx Advisory Committee.

J Neuroimmunol. 2008 Sep 15;201-202:80-4. doi: 10.1016/j.jneuroim.2008.05.031. Erratum in: J Neuroimmunol. 2009 Dec 10;217(1-2):103.

7.

Preferential expression of AChR epsilon-subunit in thymomas from patients with myasthenia gravis.

Maclennan CA, Vincent A, Marx A, Willcox N, Gilhus NE, Newsom-Davis J, Beeson D.

J Neuroimmunol. 2008 Sep 15;201-202:28-32. doi: 10.1016/j.jneuroim.2008.06.016. Epub 2008 Jul 26.

PMID:
18657869
8.

The ageing and myasthenic thymus: a morphometric study validating a standard procedure in the histological workup of thymic specimens.

Ströbel P, Moritz R, Leite MI, Willcox N, Chuang WY, Gold R, Nix W, Schalke B, Kiefer R, Müller-Hermelink HK, Jaretzki Iii A, Newsom-Davis J, Marx A.

J Neuroimmunol. 2008 Sep 15;201-202:64-73. doi: 10.1016/j.jneuroim.2008.06.017. Epub 2008 Jul 25.

PMID:
18657325
9.

Status of the thymectomy trial for nonthymomatous myasthenia gravis patients receiving prednisone.

Newsom-Davis J, Cutter G, Wolfe GI, Kaminski HJ, Jaretzki A 3rd, Minisman G, Aban I, Conwit R.

Ann N Y Acad Sci. 2008;1132:344-7. doi: 10.1196/annals.1405.014.

PMID:
18567886
10.

Congenital myasthenic syndromes and the formation of the neuromuscular junction.

Beeson D, Webster R, Cossins J, Lashley D, Spearman H, Maxwell S, Slater CR, Newsom-Davis J, Palace J, Vincent A.

Ann N Y Acad Sci. 2008;1132:99-103. doi: 10.1196/annals.1405.049.

PMID:
18567858
11.

Myasthenia gravis seronegative for acetylcholine receptor antibodies.

Vincent A, Leite MI, Farrugia ME, Jacob S, Viegas S, Shiraishi H, Benveniste O, Morgan BP, Hilton-Jones D, Newsom-Davis J, Beeson D, Willcox N.

Ann N Y Acad Sci. 2008;1132:84-92. doi: 10.1196/annals.1405.020.

PMID:
18567857
12.

The emerging diversity of neuromuscular junction disorders.

Newsom-Davis J.

Acta Myol. 2007 Jul;26(1):5-10. Review.

13.

Clinical features of the DOK7 neuromuscular junction synaptopathy.

Palace J, Lashley D, Newsom-Davis J, Cossins J, Maxwell S, Kennett R, Jayawant S, Yamanashi Y, Beeson D.

Brain. 2007 Jun;130(Pt 6):1507-15. Epub 2007 Apr 23.

PMID:
17452375
14.

Quantitative EMG of facial muscles in myasthenia patients with MuSK antibodies.

Farrugia ME, Kennett RP, Hilton-Jones D, Newsom-Davis J, Vincent A.

Clin Neurophysiol. 2007 Feb;118(2):269-77. Epub 2006 Dec 8.

PMID:
17157556
15.

Neuromyotonia: a diverse disorder.

Newsom-Davis J.

Neurol India. 2006 Dec;54(4):350. No abstract available.

16.

Can tacrolimus replace ciclosporin and prednisone to treat myasthenia gravis?

Newsom-Davis J.

Nat Clin Pract Neurol. 2005 Nov;1(1):14-5. No abstract available.

PMID:
16932485
17.

Dok-7 mutations underlie a neuromuscular junction synaptopathy.

Beeson D, Higuchi O, Palace J, Cossins J, Spearman H, Maxwell S, Newsom-Davis J, Burke G, Fawcett P, Motomura M, Müller JS, Lochmüller H, Slater C, Vincent A, Yamanashi Y.

Science. 2006 Sep 29;313(5795):1975-8. Epub 2006 Aug 17.

18.

MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.

Farrugia ME, Robson MD, Clover L, Anslow P, Newsom-Davis J, Kennett R, Hilton-Jones D, Matthews PM, Vincent A.

Brain. 2006 Jun;129(Pt 6):1481-92. Epub 2006 May 3.

PMID:
16672291
19.

Acetylcholine receptor antibody in Thai generalized myasthenia gravis patients.

Jitpimolmard S, Taimkao S, Chotmongkol V, Sawanyawisuth K, Vincent A, Newsom-Davis J.

J Med Assoc Thai. 2006 Jan;89(1):68-71.

PMID:
16583584
20.
21.

Neuromuscular junction channelopathies: a brief overview.

Newsom-Davis J.

Acta Neurol Belg. 2005 Dec;105(4):181-6. Review.

PMID:
16482866
22.

Single-fiber electromyography in limb and facial muscles in muscle-specific kinase antibody and acetylcholine receptor antibody myasthenia gravis.

Farrugia ME, Kennett RP, Newsom-Davis J, Hilton-Jones D, Vincent A.

Muscle Nerve. 2006 Apr;33(4):568-70.

PMID:
16382443
23.

Treatment for Lambert-Eaton myasthenic syndrome.

Maddison P, Newsom-Davis J.

Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003279. Review. Update in: Cochrane Database Syst Rev. 2011;(2):CD003279.

PMID:
15846654
24.

Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG.

Leite MI, Ströbel P, Jones M, Micklem K, Moritz R, Gold R, Niks EH, Berrih-Aknin S, Scaravilli F, Canelhas A, Marx A, Newsom-Davis J, Willcox N, Vincent A.

Ann Neurol. 2005 Mar;57(3):444-8.

PMID:
15732104
25.

Is "seronegative" MG explained by autoantibodies to MuSK?

Vincent AC, McConville J, Newsom-Davis J.

Neurology. 2005 Jan 25;64(2):399; author reply 399. No abstract available.

PMID:
15668461
26.

Neuromyotonia.

Newsom-Davis J.

Rev Neurol (Paris). 2004 May;160(5 Pt 2):S85-9. Review.

PMID:
15269665
27.

Seronegative myasthenia gravis.

Vincent A, McConville J, Farrugia ME, Newsom-Davis J.

Semin Neurol. 2004 Mar;24(1):125-33. Review.

PMID:
15229799
28.

Distinct phenotypes of congenital acetylcholine receptor deficiency.

Burke G, Cossins J, Maxwell S, Robb S, Nicolle M, Vincent A, Newsom-Davis J, Palace J, Beeson D.

Neuromuscul Disord. 2004 Jun;14(6):356-64.

PMID:
15145336
29.

Mutation in the AChR ion channel gate underlies a fast channel congenital myasthenic syndrome.

Webster R, Brydson M, Croxen R, Newsom-Davis J, Vincent A, Beeson D.

Neurology. 2004 Apr 13;62(7):1090-6.

PMID:
15079006
30.

Detection and characterization of MuSK antibodies in seronegative myasthenia gravis.

McConville J, Farrugia ME, Beeson D, Kishore U, Metcalfe R, Newsom-Davis J, Vincent A.

Ann Neurol. 2004 Apr;55(4):580-4.

PMID:
15048899
31.

Lambert-Eaton myasthenic syndrome.

Newsom-Davis J.

Rev Neurol (Paris). 2004 Feb;160(2):177-80. Review.

PMID:
15034474
32.

Development of a thymectomy trial in nonthymomatous myasthenia gravis patients receiving immunosuppressive therapy.

Wolfe GI, Kaminski HJ, Jaretzki A 3rd, Swan A, Newsom-Davis J.

Ann N Y Acad Sci. 2003 Sep;998:473-80.

PMID:
14592916
33.

Antibodies in myasthenia gravis and related disorders.

Vincent A, McConville J, Farrugia ME, Bowen J, Plested P, Tang T, Evoli A, Matthews I, Sims G, Dalton P, Jacobson L, Polizzi A, Blaes F, Lang B, Beeson D, Willcox N, Newsom-Davis J, Hoch W.

Ann N Y Acad Sci. 2003 Sep;998:324-35. Review.

PMID:
14592891
34.

Autoimmune disorders of neuronal potassium channels.

Newsom-Davis J, Buckley C, Clover L, Hart I, Maddison P, Tüzüm E, Vincent A.

Ann N Y Acad Sci. 2003 Sep;998:202-10. Review.

PMID:
14592877
35.

HLA-B8 in patients with the Lambert-Eaton myasthenic syndrome reduces likelihood of associated small cell lung carcinoma.

Wirtz PW, Willcox N, Roep BO, Lang B, Wintzen AR, Newsom-Davis J, Verschuuren JJ.

Ann N Y Acad Sci. 2003 Sep;998:200-1. No abstract available.

PMID:
14592876
36.

Pathogenic autoantibodies in the lambert-eaton myasthenic syndrome.

Lang B, Pinto A, Giovannini F, Newsom-Davis J, Vincent A.

Ann N Y Acad Sci. 2003 Sep;998:187-95.

PMID:
14592874
37.

Structural abnormalities of the AChR caused by mutations underlying congenital myasthenic syndromes.

Beeson D, Webster R, Ealing J, Croxen R, Brownlow S, Brydson M, Newsom-Davis J, Slater C, Hatton C, Shelley C, Colquhoun D, Vincent A.

Ann N Y Acad Sci. 2003 Sep;998:114-24.

PMID:
14592868
38.

Rapsyn mutations in hereditary myasthenia: distinct early- and late-onset phenotypes.

Burke G, Cossins J, Maxwell S, Owens G, Vincent A, Robb S, Nicolle M, Hilton-Jones D, Newsom-Davis J, Palace J, Beeson D.

Neurology. 2003 Sep 23;61(6):826-8.

PMID:
14504330
39.

Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome.

Newsom-Davis J.

Semin Neurol. 2003 Jun;23(2):191-8. Review.

PMID:
12894384
40.

Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets.

Vincent A, Bowen J, Newsom-Davis J, McConville J.

Lancet Neurol. 2003 Feb;2(2):99-106. Review.

PMID:
12849266
41.

Treatment for Lambert-Eaton myasthenic syndrome.

Maddison P, Newsom-Davis J.

Cochrane Database Syst Rev. 2003;(2):CD003279. Review. Update in: Cochrane Database Syst Rev. 2005;(2):CD003279.

PMID:
12804456
42.

Autoantibodies to IL-12 in myasthenia gravis patients with thymoma; effects on the IFN-gamma responses of healthy CD4+ T cells.

Zhang W, Liu JL, Meager A, Newsom-Davis J, Willcox N.

J Neuroimmunol. 2003 Jun;139(1-2):102-8.

PMID:
12799027
44.

Recessive inheritance and variable penetrance of slow-channel congenital myasthenic syndromes.

Croxen R, Hatton C, Shelley C, Brydson M, Chauplannaz G, Oosterhuis H, Vincent A, Newsom-Davis J, Colquhoun D, Beeson D.

Neurology. 2002 Jul 23;59(2):162-8. Erratum in: Neurology. 2009 Jan 20;72(3):294.

PMID:
12141316
45.

Phenotypic variants of autoimmune peripheral nerve hyperexcitability.

Hart IK, Maddison P, Newsom-Davis J, Vincent A, Mills KR.

Brain. 2002 Aug;125(Pt 8):1887-95.

PMID:
12135978
46.

Myasthenia gravis in a woman with congenital AChR deficiency due to epsilon-subunit mutations.

Croxen R, Vincent A, Newsom-Davis J, Beeson D.

Neurology. 2002 May 28;58(10):1563-5.

PMID:
12034803
47.

Reporting clinical trials: full access to all the data. Author's right to access to all data obtained in their study.

Rosenberg RN, Aminoff M, Boller F, Soerensen PS, Griggs RC, Hachinski V, Hallett M, Johnson RT, Kennard C, Lang AE, Lees AJ, Lisak R, Newsom-Davis J, Pedley TA, Selzer ME, Zochodne D.

J Neurol. 2002 May;249(5):638-9. No abstract available.

PMID:
12021961
48.

The action of Lambert-Eaton myasthenic syndrome immunoglobulin G on cloned human voltage-gated calcium channels.

Pinto A, Iwasa K, Newland C, Newsom-Davis J, Lang B.

Muscle Nerve. 2002 May;25(5):715-24.

PMID:
11994966
49.

Thymic myoid cells and germinal center formation in myasthenia gravis; possible roles in pathogenesis.

Roxanis I, Micklem K, McConville J, Newsom-Davis J, Willcox N.

J Neuroimmunol. 2002 Apr;125(1-2):185-97.

PMID:
11960656
50.

Reporting clinical trials: full access to all the data.

Rosenberg RN, Aminoff M, Boller F, Soerensen PS, Griggs RC, Hallett M, Johnson RT, Kennard C, Lang AE, Lees AJ, Lisak R, Newsom-Davis J, Pedley TA, Selzer ME, Zochodne D.

Neurorehabil Neural Repair. 2001;15(3):157-8. No abstract available.

PMID:
11944735

Supplemental Content

Loading ...
Support Center